1
|
Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Local Tissue Damage Induced by a Type P-I Snake Venom Metalloproteinase. Toxins (Basel) 2019; 12:toxins12010008. [PMID: 31861940 PMCID: PMC7020480 DOI: 10.3390/toxins12010008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/07/2019] [Accepted: 12/12/2019] [Indexed: 12/16/2022] Open
Abstract
Snake bite envenoming is a public health problem that was recently included in the list of neglected tropical diseases of the World Health Organization. In the search of new therapies for the treatment of local tissue damage induced by snake venom metalloproteinases (SVMPs), we tested the inhibitory activity of peptidomimetic compounds designed as inhibitors of matrix metalloproteinases on the activities of the SVMP Batx-I, from Bothrops atrox venom. The evaluated compounds show great potential for the inhibition of Batx-I proteolytic, hemorrhagic and edema-forming activities, especially the compound CP471474, a peptidomimetic including a hydroxamate zinc binding group. Molecular dynamics simulations suggest that binding of this compound to the enzyme is mediated by the electrostatic interaction between the hydroxamate group and the zinc cofactor, as well as contacts, mainly hydrophobic, between the side chain of the compound and amino acids located in the substrate binding subsites S1 and S1′. These results show that CP471474 constitutes a promising compound for the development of co-adjuvants to neutralize local tissue damage induced by snake venom metalloproteinases.
Collapse
|
2
|
Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. Cancers (Basel) 2019; 11:cancers11030356. [PMID: 30871206 PMCID: PMC6468645 DOI: 10.3390/cancers11030356] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Revised: 02/21/2019] [Accepted: 03/09/2019] [Indexed: 12/22/2022] Open
Abstract
Malignant melanoma is the most aggressive and treatment resistant type of skin cancer. It is characterized by continuously rising incidence and high mortality rate due to its high metastatic potential. Various types of cell adhesion molecules have been implicated in tumor progression in melanoma. One of these, the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), is a multi-functional receptor protein potentially expressed in epithelia, endothelia, and leukocytes. CEACAM1 often appears in four isoforms differing in the length of their extracellular and intracellular domains. Both the CEACAM1 expression in general, and the ratio of the expressed CEACAM1 splice variants appear very dynamic. They depend on both the cell activation stage and the cell growth phase. Interestingly, normal melanocytes are negative for CEACAM1, while melanomas often show high expression. As a cell–cell communication molecule, CEACAM1 mediates the direct interaction between tumor and immune cells. In the tumor cell this interaction leads to functional inhibitions, and indirectly to decreased cancer cell immunogenicity by down-regulation of ligands of the NKG2D receptor. On natural killer (NK) cells it inhibits NKG2D-mediated cytolysis and signaling. This review focuses on novel mechanistic insights into CEACAM1 isoforms for NK cell-mediated immune escape mechanisms in melanoma, and their clinical relevance in patients suffering from malignant melanoma.
Collapse
|
3
|
Wang N, Wang Q, Chi J, Xiang F, Lin M, Wang W, Wei F, Feng Y. Carcinoembryonic antigen cell adhesion molecule 1 inhibits the antitumor effect of neutrophils in tongue squamous cell carcinoma. Cancer Sci 2019; 110:519-529. [PMID: 30565803 PMCID: PMC6361565 DOI: 10.1111/cas.13909] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 11/30/2018] [Accepted: 12/05/2018] [Indexed: 12/26/2022] Open
Abstract
Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), a transmembrane glycoprotein, has multiple functions. In tongue squamous cell carcinoma (TSCC), CEACAM1 overexpression is correlated with neutrophil infiltration, and both are associated with poor clinical outcomes. However, the mechanism underlying CEACAM1's effect on neutrophil function in TSCC remains unclear. We cocultured tongue carcinoma cells overexpressing CEACAM1‐4L, CEACAM1‐4S and differentiated HL‐60 cells. This significantly upregulated the expression of MMP‐9, interleukin 8, and VEGF‐A in the differentiated HL‐60 cells and downregulated the expression of TNF‐α, relative to vector and blank control groups (P < 0.05). Additionally, CEACAM1 overexpression in tongue carcinoma cells weakened the cytotoxicity of differentiated HL‐60 cells in the coculture system (P < 0.05). Thus, CEACAM1 expression in TSCC may induce an antitumor to protumor transformation of neutrophils. We performed qRT‐PCR and ELISA to evaluate the underlying mechanism, and found that CEACAM1 expression in tongue carcinoma cells upregulated transforming growth factor β1 (TGF‐β1) expression, while blocking of TGF‐β1 inhibited the neutrophils’ changes in the coculture system. Immunohistochemical analysis of clinical specimens revealed strong expression of TGF‐β1 protein in TSCC. TGF‐β1 expression was positively correlated with CEACAM1 expression, lymph node metastasis, and tumor recurrence. Double immunofluorescence results revealed colocalization of CEACAM1 and TGF‐β1 protein in TSCC. A xenograft nude mouse model revealed that CEACAM1 overexpression in TSCC promoted tumor formation and growth, and was associated with more neutrophils infiltration. Our results indicate that CEACAM1 overexpression in TSCC may induce transformation of neutrophils from antitumor to protumor type via TGF‐β1, which may further promote tumor progression.
Collapse
Affiliation(s)
- Ning Wang
- Department of Pathology, School of Basic Medicine, Medical College of Qingdao University, Qingdao, China
| | - Qingjie Wang
- Institute of Basic Medical Sciences, Qilu Hospital, Shandong University, Jinan, China
| | - Jinghua Chi
- Department of Pathology, School of Basic Medicine, Medical College of Qingdao University, Qingdao, China
| | - Fenggang Xiang
- Department of Pathology, School of Basic Medicine, Medical College of Qingdao University, Qingdao, China
| | - Mei Lin
- Department of Pathology, School of Basic Medicine, Medical College of Qingdao University, Qingdao, China
| | - Wenhong Wang
- Department of Pathology, School of Basic Medicine, Medical College of Qingdao University, Qingdao, China
| | - Fengcai Wei
- Department of Stomatology, Qilu Hospital, Institute of Stomatology, Shandong University, Jinan, China
| | - Yuanyong Feng
- Department of Oral and Maxillofacial Surgery, School of Stomatology and Affiliated Hospital of Qingdao University, Qingdao, China
| |
Collapse
|
4
|
Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients. DISEASE MARKERS 2018; 2018:6714287. [PMID: 30050594 PMCID: PMC6046165 DOI: 10.1155/2018/6714287] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 05/31/2018] [Indexed: 01/01/2023]
Abstract
The underlying mechanisms of ovarian cancer (OvCa) dissemination are still poorly understood, and novel molecular markers for this cancer type are urgently needed. In search of adhesion molecules with prognostic relevance in OvCa, we compared tumors with good outcome (alive > 3 years) and those with poor outcome (dead < 2 years) within data from The Cancer Genome Atlas (TCGA). The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) turned out as the only gene with differential expression in these groups. In order to further investigation on its role in OvCa, we analyzed CEACAM1 mRNA levels extracted from TCGA microarray data (n = 517) as well as CEACAM1 protein expression by Western blot analysis in a cohort of 242 tumor samples. Further, CEACAM1 localization in tumour tissue was evaluated by immunohistochemistry and CEACAM1 splice variants by RT-PCR in representative tumours. In Kaplan–Meier analysis, high CEACAM1 mRNA levels significantly correlated with longer survival (p = 0.008). By Western blot analysis in the second cohort, similar associations of high CEACAM1 protein levels with longer recurrence-free survival (RFS, p = 0.035) and overall survival (OAS, p = 0.004) were observed. In multivariate Cox regression analysis including clinical prognostic parameters, CEACAM1 mRNA or protein expression turned out as independent prognostic markers. Stratified survival analysis showed that high CEACAM1 protein expression was prognostic in node-negative tumors (p = 0.045 and p = 0.0002 for DFS and OAS) but lost prognostic significance in node-positive carcinomas. Similarly, high CEACAM1 mRNA expression did not show prognostic relevance in tumors with lymphatic invasion (L1) but was associated with longer survival in cases without lymphovascular involvement. Further analysis showed a predominance of 4S and 4L isoforms and mostly membraneous CEACAM1 localization in ovarian tumours. Our results suggest that CEACAM1 might be an independent favorable prognostic marker in OvCa, especially in the subgroup of patients with solely intraperitoneal metastasis.
Collapse
|
5
|
Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. Neoplasia 2018; 20:401-409. [PMID: 29558679 PMCID: PMC5909674 DOI: 10.1016/j.neo.2018.01.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 01/25/2018] [Accepted: 01/29/2018] [Indexed: 12/21/2022] Open
Abstract
BRAF becomes constitutively activated in 50% to 70% of melanoma cases. CEACAM1 has a dual role in melanoma, including facilitation of cell proliferation and suppression of infiltrating lymphocytes, which are consistent with its value as a marker for poor prognosis in melanoma patients. Here we show that BRAFV600E melanoma cells treated with BRAF and MEK inhibitors (MAPKi) downregulate CEACAM1 mRNA and protein expression in a dose- and exposure time–dependent manners. Indeed, there is a significant correlation between the presence of BRAFV600E and CEACAM1 expression in melanoma specimens obtained from 45 patients. Vemurafenib-resistant cell systems reactivate the MAPK pathway and restore basal CEACAM1 mRNA and protein levels. These combined results suggest transcriptional regulation. Indeed, luciferase reporting assays show that CEACAM1 promoter (CEACAM1p) activity is significantly reduced by MAPKi. Importantly, we show that the MAPK-driven CEACAM1p activity is mediated by ETS1, a major transcription factor and downstream effector of the MAPK pathway. Phosphorylation mutant ETS1T38A shows a dominant negative effect over CEACAM1 expression. The data are consistent with independent RNAseq data from serial biopsies of melanoma patients treated with BRAF inhibitors, which demonstrate similar CEACAM1 downregulation. Finally, we show that CEACAM1 downregulation by MAPKi renders the cells more sensitive to T-cell activation. These results provide a new view on a potential immunological mechanism of action of MAPKi in melanoma, as well as on the aggressive phenotype observed in drug-resistant cells.
Collapse
Affiliation(s)
- Karin Kfir-Elirachman
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Rona Ortenberg
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel
| | - Bella Vizel
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Michal J Besser
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Iris Barshack
- Institute of Pathology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, 5262620, Israel
| | - Jacob Schachter
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, 5262620, Israel
| | - Yael Nemlich
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel
| | - Gal Markel
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat-Gan, 5262620, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| |
Collapse
|
6
|
Crépin R, Gentien D, Duché A, Rapinat A, Reyes C, Némati F, Massonnet G, Decaudin D, Djender S, Moutel S, Desrumeaux K, Cassoux N, Piperno-Neumann S, Amigorena S, Perez F, Roman-Roman S, de Marco A. Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts. Pigment Cell Melanoma Res 2017; 30:317-327. [DOI: 10.1111/pcmr.12577] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 01/23/2017] [Indexed: 12/13/2022]
Affiliation(s)
- Ronan Crépin
- Tumor Target and Therapeutic Antibody - Identification Platform (TAb-IP); Paris Cedex 05 France
| | - David Gentien
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Angeline Duché
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Audrey Rapinat
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Cecile Reyes
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Fariba Némati
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Gérald Massonnet
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Didier Decaudin
- Translational Research Department; Institut Curie; PSL Research University; Paris France
- Medical Oncology Department; Institut Curie; Paris Cedex 05 France
| | - Selma Djender
- Tumor Target and Therapeutic Antibody - Identification Platform (TAb-IP); Paris Cedex 05 France
- Institut Curie; PSL Research University; Paris Cedex 05 France
| | - Sandrine Moutel
- Translational Research Department; Institut Curie; PSL Research University; Paris France
- Institut Curie; PSL Research University; Paris Cedex 05 France
- UMR144; Institut Curie; Paris France
| | - Klervi Desrumeaux
- Tumor Target and Therapeutic Antibody - Identification Platform (TAb-IP); Paris Cedex 05 France
| | | | | | - Sebastian Amigorena
- Institut Curie; PSL Research University; Paris Cedex 05 France
- INSERM Unit 932; Paris cedex 05 France
- SIRIC INCa-DGOS-4654; Paris France
- CIC IGR Curie 1428; Paris France
| | - Franck Perez
- Tumor Target and Therapeutic Antibody - Identification Platform (TAb-IP); Paris Cedex 05 France
- Institut Curie; PSL Research University; Paris Cedex 05 France
- UMR144; Institut Curie; Paris France
| | - Sergio Roman-Roman
- Translational Research Department; Institut Curie; PSL Research University; Paris France
| | - Ario de Marco
- Tumor Target and Therapeutic Antibody - Identification Platform (TAb-IP); Paris Cedex 05 France
- SIRIC INCa-DGOS-4654; Paris France
- CIC IGR Curie 1428; Paris France
- Department of Biomedical Sciences and Engineering; University of Nova Gorica (UNG); Vipava Slovenia
| |
Collapse
|